Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia; British Journal of Clinical Pharmacology; Vol. 86, iss. 9

Detaylı Bibliyografya
Parent link:British Journal of Clinical Pharmacology
Vol. 86, iss. 9.— 2020.— [P. 1827-1835]
Müşterek Yazar: Национальный исследовательский Томский политехнический университет Инженерная школа неразрушающего контроля и безопасности Отделение контроля и диагностики
Diğer Yazarlar: Geers L. M., Pozhidaev I. V. Ivan, Ivanova S. A. Svetlana Aleksandrovna, Freydin M. B. Maksim Borisovich, Schmidt A. F. Amand, Cohen D., Boyko A. S., Paderina D. Z. Diana, Fedorenko O. Yu. Olga Yurievna, Semke A. V., Bokhan N. A. Nikolay Aleksandrovich, Wilffert B. Bob, Kosterink J. G.W. Jos, Touw D. J., Loonen A. J. M Anton
Özet:Title screen
Hyperprolactinaemia, a common adverse effect of antipsychotic drugs, is primarily linked to blockade of dopamine D2 receptors in the pituitary gland. Certain antipsychotic drugs, such as, for example risperidone and paliperidone, are more likely to induce hyperprolactinaemia compared to others. This effect is probably caused by a relatively high blood/brain concentration ratio, a consequence of being a substrate of P‐glycoprotein. Genetic variants of P‐glycoprotein with changed functional activity might influence the potential of risperidone and paliperidone to cause hyperprolactinaemia as the altered blood/brain concentration ratio would lead to a reduced therapeutic drug level within essential brain areas making dose adaptations necessary. This increases exposure of dopamine D2 receptors within the pituitary gland.
Режим доступа: по договору с организацией-держателем ресурса
Dil:İngilizce
Baskı/Yayın Bilgisi: 2020
Konular:
Online Erişim:https://doi.org/10.1111/bcpt.13173
Materyal Türü: Elektronik Kitap Bölümü
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664042

Benzer Materyaller